Chemoimmunotherapy with O-FC previously untreated patients with chronic lymphocytic leukemia

Abstrakt

We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). O-FC is active and safe in treatment-naive patients with CLL, including high-risk patients.

Klíčová slova

• chemoimmunotherapy
• O-FC
• chronic lymphocytic leukemia